Skip to content
Review

Galantamine in Alzheimer’s disease and mild cognitive impairment: updated review of the evidence

Sep 2026 · BJ Psych Advances · Vol 32, pp. 280 - 283 · 0 citations · 11 references

TL;DR

It is proposed that the characteristics of the patient sample limit the external validity of the findings, and that the research question, although valid, is of limited practical importance.

Abstract

SUMMARY Alzheimer’s disease is a progressive and incurable condition and the leading cause of dementia worldwide. Lim et al’s (2024) Cochrane Review on the acetylcholinesterase inhibitor galantamine and its effects in Alzheimer’s disease and mild cognitive impairment (MCI) concluded that the drug slows cognitive and functional decline in Alzheimer’s disease, but not in MCI. However, in several studies the handling of data after drop-out was a potential source of bias. In this month’s Round the Corner, we also propose that the characteristics of the patient sample limit the external validity of the findings, and that the research question, although valid, is of limited practical importance.

View source

Similar papers

Open access Sep 2026

Acetylcholinergic therapy of Alzheimer’s disease and mixed dementia

Introduction . Cognitive impairment, reaching the level of dementia, is one of the leading causes of death and disability in many countries. According to international epidemiological studies, Alzheimer’s disease (AD) and its combination with cerebrovascular pathology account for 60–80% of all cases of dementia. Giv...

D. Grishina, V. V. Zakharov, A. V. Lokshina · 0 citations
Review Open access Sep 2026

A Review of Dementia with Emphasis on Alzheimer’s Disease

Dementia is a type of neurocognitive disorder (NCD) among others like delirium, amnesia, and other cognitive disorders due to traumatic brain injury, substance/medication use, HIV infection, prion disease, Parkinson disease, Huntington’s disease, and other medical conditions. Patients usually present with declining c...

Victoria Githenya · 0 citations
Review Open access Oct 2026

Cognitive Reserve: White Matter, Microvascular, Glymphatic and Cholinergic Dysfunction in Alzheimer’s Disease

Late-onset Alzheimer’s disease (LOAD) is a cognitive disorder that leads to the requirement of full-time care. The ever-increasing growth of the LOAD population demands that more research be dedicated to the discovery/design of effective therapeutics. The two major hypotheses that have been evaluated in the clinic incl...

Paul L. Wood · 0 citations

Anxiety: An early indicator of Alzheimer's disease?

The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of Alzheimer's disease in older adults, and suggest depression and other neuropsychiatric symptoms may be predictors of AD's progression during its "preclinical" phase.

Unknown authors · 0 citations
Open access Oct 2026

A New Era in Alzheimer’s Disease Diagnosis: The Promise of Blood-Based Biomarkers for Better Management and Treatment

September is World Alzheimer’s Month, various awareness activities are organized throughout the globe. Alzheimer’s disease (AD), the most common cause of dementia, represents one of the greatest challenges to healthy ageing and public health. Its progressive deterioration of memory, cognition, behaviour, and functional...

H. Joshi · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.